Display options
Cite
Matsuoka K, Saito E, Fujii T, et al. Tacrolimus for the Treatment of Ulcerative Colitis. Intest Res. 2015;13(3):219-26doi: 10.5217/ir.2015.13.3.219.
Matsuoka, K., Saito, E., Fujii, T., Takenaka, K., Kimura, M., Nagahori, M., Ohtsuka, K., & Watanabe, M. (2015). Tacrolimus for the Treatment of Ulcerative Colitis. Intestinal research, 13(3), 219-26. https://doi.org/10.5217/ir.2015.13.3.219
Matsuoka, Katsuyoshi, et al. "Tacrolimus for the Treatment of Ulcerative Colitis." Intestinal research vol. 13,3 (2015): 219-26. doi: https://doi.org/10.5217/ir.2015.13.3.219
Matsuoka K, Saito E, Fujii T, Takenaka K, Kimura M, Nagahori M, Ohtsuka K, Watanabe M. Tacrolimus for the Treatment of Ulcerative Colitis. Intest Res. 2015 Jul;13(3):219-26. doi: 10.5217/ir.2015.13.3.219. Epub 2015 Jun 09. PMID: 26130996; PMCID: PMC4479736.
Copy Download .nbib Format: NLM
Share it on

Intest Res. 2015 Jul;13(3):219-26. doi: 10.5217/ir.2015.13.3.219. Epub 2015 Jun 09.

Tacrolimus for the Treatment of Ulcerative Colitis.

Intestinal research

Katsuyoshi Matsuoka, Eiko Saito, Toshimitsu Fujii, Kento Takenaka, Maiko Kimura, Masakazu Nagahori, Kazuo Ohtsuka, Mamoru Watanabe

Affiliations

  1. Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University, Tokyo, Japan.

PMID: 26130996 PMCID: PMC4479736 DOI: 10.5217/ir.2015.13.3.219

Abstract

Tacrolimus is a calcineurin inhibitor used for the treatment of corticosteroid-refractory ulcerative colitis (UC). Two randomized controlled trials and a number of retrospective studies have assessed the therapeutic effect of tacrolimus in UC patients. These studies showed that tacrolimus has excellent short-term efficacy in corticosteroid-refractory patients, with the rates of clinical response ranging from 61% to 96%. However, the long-term prognosis of patients treated with tacrolimus is disappointing, and almost 50% of patients eventually underwent colectomy in long-term follow-up. Tacrolimus can achieve mucosal healing in 40-50% of patients, and this is associated with a favorable long-term prognosis. Anti-tumor necrosis factor (TNF)-α antibodies are another therapeutic option in corticosteroid-refractory patients. A prospective head-to-head comparative study of tacrolimus and infliximab is currently being performed to determine which treatment is more effective in corticosteroid-refractory patients. Several retrospective studies have demonstrated that switching between tacrolimus and anti-TNF-α antibody therapy was effective in patients who were refractory to one of the treatments. Most adverse events of tacrolimus are mild; however, opportunistic infections, especially pneumocystis pneumonia, are the most important adverse events, and these should be carefully considered during treatment. Several issues on tacrolimus treatment in UC patients remain unsolved (e.g., use of tacrolimus as remission maintenance therapy). Further controlled studies are needed to optimize the use of tacrolimus for the treatment of UC.

Keywords: Calcineurin inhibitors; Colitis, ulcerative; Cyclosporine; Tacrolimus

References

  1. Lancet. 2012 Dec 1;380(9857):1909-15 - PubMed
  2. J Antibiot (Tokyo). 1987 Sep;40(9):1256-65 - PubMed
  3. Inflamm Bowel Dis. 2009 Feb;15(2):193-8 - PubMed
  4. Gut. 2011 Jun;60(6):780-7 - PubMed
  5. Dig Liver Dis. 2014 Oct;46(10):875-80 - PubMed
  6. World J Gastroenterol. 2015 Feb 14;21(6):1880-6 - PubMed
  7. Int Immunopharmacol. 2002 Jul;2(8):1055-63 - PubMed
  8. Inflamm Bowel Dis. 2012 May;18(5):803-8 - PubMed
  9. J Gastroenterol Hepatol. 2012 Mar;27(3):487-92 - PubMed
  10. Aliment Pharmacol Ther. 2008 Sep 1;28(5):589-97 - PubMed
  11. Am J Gastroenterol. 2011 Apr;106(4):771-7 - PubMed
  12. Aliment Pharmacol Ther. 2008 Nov 15;28(10):1214-20 - PubMed
  13. J Crohns Colitis. 2013 Dec;7(12):e609-14 - PubMed
  14. Arzneimittelforschung. 2008;58(5):242-7 - PubMed
  15. Inflamm Bowel Dis. 2002 Sep;8(5):317-24 - PubMed
  16. Inflamm Bowel Dis. 2007 Feb;13(2):129-34 - PubMed
  17. Digestion. 2014;89(1):55-60 - PubMed
  18. Gut. 2006 Sep;55(9):1255-62 - PubMed
  19. Aliment Pharmacol Ther. 2010 May;31(9):1036-41 - PubMed
  20. Dig Dis Sci. 2006 Oct;51(10):1833-40 - PubMed
  21. N Engl J Med. 2005 Dec 8;353(23):2462-76 - PubMed
  22. ISRN Gastroenterol. 2013 Apr 09;2013:304894 - PubMed
  23. Dis Colon Rectum. 2013 Oct;56(10):1166-73 - PubMed
  24. J Gastroenterol Hepatol. 2010 May;25(5):886-91 - PubMed
  25. J Crohns Colitis. 2013 Dec;7(11):e516-21 - PubMed
  26. J Crohns Colitis. 2010 Nov;4(5):606-9 - PubMed
  27. BMJ Open Gastroenterol. 2015 Feb 20;2(1):e000021 - PubMed
  28. J Clin Gastroenterol. 2011 Jul;45(6):526-30 - PubMed
  29. J Pediatr. 2000 Dec;137(6):794-9 - PubMed
  30. J Crohns Colitis. 2012 Jul;6(6):681-6 - PubMed
  31. Am J Gastroenterol. 2006 May;101(5):1048-56 - PubMed
  32. Inflamm Bowel Dis. 2011 Jan;17(1):22-9 - PubMed
  33. Digestion. 2014;89(1):88-103 - PubMed
  34. Clin Pharmacol Ther. 2011 Mar;89(3):422-8 - PubMed
  35. Dig Liver Dis. 2015 May;47(5):365-71 - PubMed
  36. N Engl J Med. 1994 Jun 30;330(26):1841-5 - PubMed
  37. Am J Gastroenterol. 1998 Oct;93(10):1860-6 - PubMed
  38. Aliment Pharmacol Ther. 2003 May 15;17(10):1273-81 - PubMed
  39. Aliment Pharmacol Ther. 2013 Aug;38(3):294-302 - PubMed
  40. Inflamm Bowel Dis. 2014 Aug;20(8):1375-81 - PubMed
  41. Inflamm Bowel Dis. 2008 Jan;14(1):7-12 - PubMed
  42. Aliment Pharmacol Ther. 2013 Jan;37(1):129-36 - PubMed
  43. Eur J Gastroenterol Hepatol. 2013 Jun;25(6):714-8 - PubMed
  44. J Gastroenterol Hepatol. 2014 Jan;29(1):60-6 - PubMed
  45. J Pediatr Gastroenterol Nutr. 2007 Sep;45(3):306-11 - PubMed
  46. Inflamm Bowel Dis. 2013 Jun;19(7):1490-8 - PubMed
  47. Aliment Pharmacol Ther. 2003 Aug 15;18(4):415-23 - PubMed

Publication Types